Peroxisome-proliferator-activated-receptor-gamma (PPAR-γ) is implicated, in some capacity, in the pathogenesis of pulmonary arterial hypertension (PAH). Rosiglitazone, an oral antidiabetic and PPAR-γ agonist, has the potential to dilate pulmonary arteries and to attenuate arterial remodeling in PAH. Here, we sought to test the hypothesis that rosiglitazone can be repurposed as inhaled formulation for the treatment of PAH. We have tested this conjecture by preparing and optimizing poly(lactic-co-glycolic) acid (PLGA) based particles of rosiglitazone, assessing the drug particles for pulmonary absorption, investigating the efficacy of the plain versus particulate drug formulation in improving the respiratory hemodynamics in PAH animals, and finally studying the effect of the drug in regulating the molecular markers associated with PAH pathogenesis. The optimized particles were slightly porous and spherical, and released 87.9% ± 6.7% of the drug in 24 h. The elimination half-life of the drug formulated in PLGA particles was 2.5-fold greater than that of the plain drug administered via the same route at the same dose. The optimized formulation, given via the pulmonary route, produced pulmonary selective vasodilation in PAH animals, but oral rosiglitazone had no effect in pulmonary hemodynamics. Rosiglitazone ameliorates the pathogenesis of PAH by balancing the molecular regulators involved in the vasoconstriction and vasodilation of human pulmonary arterial smooth muscle cells. All in all, data generated using intact animal and cellular models point to the conclusion that PLGA particles of an antidiabetic drug can be used for the treatment of a different disease, PAH.
Introduction
Peroxisome proliferator-activated receptor-γ (PPAR-γ), a ligand-activated nuclear transcription factor (TF), is known to regulate various cellular and physiological processes including cell differentiation, lipid metabolism, inflammation, and tumorigenesis [1] . A wealth of published data point to PPAR-γ's association with the pathogenesis of pulmonary arterial hypertension (PAH) [1] [2] [3] [4] , a debilitating disease that encompasses various pathological conditions characterized by a mean pulmonary arterial pressure (mPAP) of ≥25 mmHg at rest with a normal mean pulmonary capillary wedge pressure (≤15 mmHg). This disease affects persons of every ethnicity and age, including children, claiming > 15,000 lives a year [5] . Pulmonary arterial endothelial cells (PAECs), smooth muscle cells (PASMCs), and fibroblasts are intricately implicated in the development and progression of PAH. In healthy PAECs and PASMCs, PPAR-γ is profusely expressed, but its expression declines dramatically in the PAECs and PASMCs of PAH afflicted patients and animals. Importantly, the levels of PPAR-γ drops even further in the plexiform lesions of human subjects with PAH [2] . Further, the erasure of PPAR-γ from PAECs and PASMCs elicits spontaneous PAH [6] and activation of PPAR-γ slows the PAH development. Thus PPAR-γ has been proposed to be an important therapeutic target for PAH [3] .controversy surrounding its effects on the cardiovascular health of diabetic patients [8] . However, because of the possible role of PPAR-γ in PAH pathogenesis, rosiglitazone has been reported to slow PASMC proliferation by modulating cell growth and apoptosis [9, 10] . Rosiglitazone reduces mPAP in both monocrotaline-and chronic hypoxia-induced animal models of PAH [11, 12] . Unlike other anti-PAH drugs, which reduce only mPAP but have little or no direct effect on vascular remodeling in PAH, rosiglitazone appears to reduce PAH associated right ventricular hypertrophy and pulmonary vascular remodeling in PAH animals [10] . Thus, rosiglitazone can presumably be repurposed into a potent anti-PAH drug.
However, no studies have thus far systematically evaluated the feasibility of repurposing rosiglitazone for the treatment of PAH, despite its potential in ameliorating various pathological aspects of PAH. Published studies, for example, assessed the anti-PAH efficacy of rosiglitazone in monocrotaline-or hypoxia-induced PAH models [13] , but not in Sugen/hypoxia model, an animal model that develops a severe form of PAH and exhibits the hallmarks of human PAH [14] . However, the feasibility of an inhaled formulation of rosiglitazone has not yet been established; to date, no study has taken a systematic approach to prepare any PLGA particles of rosiglitazone for inhalational delivery. Further, the relative absorption and efficacy of the drug in reducing mPAP after oral versus pulmonary administration of the drug or its formulation remain unknown. Previously reported preclinical and clinical studies point to the changes in the expression of molecular regulators such as endothelial nitric oxide synthase (eNOS), endothelin 1 (ET-1), and NOX4 in PAH associated endothelial dysfunction and PASMC hyperproliferation [6, 15, 16] . However, the effects of rosiglitazone on PAH afflicted human ECs (PAH-ECs) and SMCs (PAH-SMCs ) have not yet been elucidated. To fill these gaps and to deploy rosiglitazone in PAH therapy, here we propose to test the hypothesis that rosiglitazone, formulated in PLGA particles, is repurpose-able for pulmonary selective therapy of PAH and that rosiglitazone affects signaling molecules that regulate the proliferation and remodeling of PAECs and PASMCs of idiopathic pulmonary arterial hypertension (IPAH) patients.
Thus, with a goal to find a new therapeutic application of an old drug, we prepared PLGA particles of rosiglitazone and tested the formulation in Sugen/Hypoxia induced PAH rats. After optimizing and characterizing the PLGA particles of the drug, we assessed the pharmacokinetics of both plain drug and drug particles, and investigated the pulmonary absorption and efficacy of the plain drug and formulations in reducing mPAP after oral or intratracheal administration. Using ECs and SMCs of human idiopathic PAH patients and employing western blot analysis, we determined the effect of the drug on modulating various signaling molecules including PPARγ, eNOS, ET-1 and NOX-4 and investigated the anti-proliferative effects of rosiglitazone. We also assessed the safety of the drug for inhalational delivery by measuring interleukin-6 (IL-6), tumor necrosis factor α (TNF-α), and CTRP1 protein in the bronchoalveolar lavage fluid.
Materials and methods

Materials
PLGA polymers (lactate-to-glycolate ratio of 50:50; inherent viscosity 0.55-0.75 dL/g) were purchased from Lactel Absorbable Polymers (Birmingham, AL) and rosiglitazone maleate from Cayman Chemical (Ann Arbor, MI). Male Sprague-Dawley rats (250-350 g) were supplied by Charles River Laboratories (Wilmington, MA). PAH afflicted ECs (PAH-ECs) and SMCs (PAH-SMCs) were obtained from Pulmonary Arterial Hypertension Breakthrough Initiative (PHBI, University of Pennsylvania, PA), under an approved protocol for the use of human cells. We procured primary antibodies for PPAR-γ, NOX4, endothelin 1 (ET-1), and endothelial nitric oxide synthase (eNOS) from Bethyl Laboratories Inc. (Montgomery, TX) and ProSci Inc. (Poway, CA), ThermoFisher Scientific (Waltham, MA), and BD Biosciences (San Jose, CA), respectively. Other supplies for western blot were purchased from Bio-Rad laboratories (Hercules, CA). For cell proliferation studies, Cell Counting Kit-8 was purchased from Sigma-Aldrich (St. Louis, MO). All other chemicals were of LCMS or UPLC grades and purchased from Sigma-Aldrich (St. Louis, MO).
Methods
Preparation of PLGA particles of rosiglitazone
Following our published protocols [17] , we used a water-in-oil-inwater (W 1 /O/W 2 ) double emulsion-solvent evaporation method to prepare rosiglitazone loaded particles [18] . First, we emulsified, using a sonicator (Branson Ultrasonics Inc., CT), a 0.5 mL of internal aqueous phase (IAP, W 1 ), containing rosiglitazone maleate (20 mg/mL) dissolved in a solution of methanol plus double-deionized water, with an organic phase (OP), comprising PLGA plus 0.5% polyethyleneimine, a porosigen, in a water-dichloromethane mixture. We then prepared a double emulsion by homogenizing the above primary (W 1 /O) emulsion with 0.5% w/v polyvinyl alcohol (PVA) solution (EAP, W 2 ) and stirred the resulting double emulsion for 8 h at the room temperature, and so to evaporate dichloromethane and cure the particles. After washing the polymeric particles thrice with water, we lyophilized them for 48 h and stored the free-flowing powdered formulations at 4°C for further studies. We prepared an array of formulations by using the same protocol and assessed the influence of three input parameters (PLGA concentrations, PVA concentrations and homogenization rates) on three output parameters: particle size, entrapment efficiency, and drug loading. We performed statistical response optimization study to identify the optimal process parameters that yielded particles with favorable characteristics [19] .
Physical characterization of rosiglitazone particles
We used various instrumental techniques to evaluate the rosiglitazone-loaded particles for their morphology, size, aerodynamic properties, and zeta potential. In a Hitachi S-4300 (Freehold, NJ) scanning electron microscope (SEM), we examined the morphology of particles and in a Mastersizer 2000 (Malvern® Instruments Ltd., Malvern, UK) equipped with a Hydro® 2000MU sample dispersion unit, we determined the volume-based mean diameter (D v ) and particle size distribution. For measuring D v , we dispersed freeze-dried particles (~15 mg) in deionized water and then pumped the particle dispersion into the particle size analyzer. For zeta potential measurement, we used a Nano ZS90 Zetasizer (Malvern Instruments Ltd., Malvern, UK) and determined the zeta potential after dispersing the particles in 1× PBS buffer. To assess whether the particle size changes due to the aerosolization, we sprayed a suspension of particles using an aerosolizer for rats (Penn Century, Philadelphia, PA), which we have used below for administering the drug or formulations, onto a Petri dish, collected the particles from the Petri dish, and measured the particle size as discussed above.
In an eight-stage Marc-II Andersen Cascade Impactor (Westech Scientific Inc., Marietta, GA), we determined the particles' mass median aerodynamic diameters (MMADs) in triplicates. After loading preweighed glass fiber filter papers onto the plates of each stage and using a HandiHaler® (Pfizer Inc., NJ New York, NY), we let the particles move through the impactor at a flow rate of 28.3 L/min, and recorded the amount of particles deposited on each stage by subtracting the weight of the filter papers taken after passing the particle through the impactor from that taken before placing the papers in the impactor. Later, in a semi-log graph paper, we plotted the percentage of cumulative amount of particles deposited in each stage against the effective cut-off diameter (μm) of various stages and read the MMAD from the plot.
Entrapment efficiency
For determination of entrapment efficiency, we first dissolved 5 mg of freeze-dried particles in a 70:30 mixture of methanol-dimethyl sulfoxide, centrifuged, and read the absorbance of the supernatant at 293 nm in a spectrophotometer (Hewlett Packard, Palo Alto, CA). We measured the drug concentration from a calibration curve by plotting drug concentration versus absorbance.
Release of rosiglitazone in-vitro
In a simulated lung fluid (SLF), prepared according to the Moss formula [20] plus 0.1% Tween® 80 at 37 ± 1°C and a pH of 7.4, we assessed the in vitro release pattern of rosiglitazone from the optimized particles. Suspending an aliquot of freeze-dried particles (10 mg) in 1 mL SLF, we collected an aliquot of samples (100 μL) for 36 h at varying time intervals and assayed the drug concentration in an AC-QUITY ultra-high-performance-liquid-chromatographic (UPLC) H-Class System (Waters Corporation, Milford, MA). After diluting the samples with the mobile phase and centrifuging the solution at 17,000g, we separated the drug in a Kinetex® C18 UPLC column (50 mm × 2.1 mm, 3 μm; Phenomenex Inc., Torrance, CA) via gradient elution in a mobile phase, comprising 0.1% formic acid in water and 0.1% formic acid in methanol, flowed at 0.25 mL/min. Sildenafil citrate, at a concentration of 200 μg/mL, was used as an internal standard.
Safety studies in bronchoalveolar lavage (BAL) fluid
To evaluate toxicity of the particles after acute administration, we analyzed the BAL fluid, collected from the lungs treated with intratracheal particles, for two known injury markers: lactate dehydrogenase (LDH) and alkaline phosphatase (ALP) [21] . Four groups of male SD rats (n = 3-4), anesthetized with a cocktail of ketamine/xylazine received (i) saline, (ii) 0.1 μg/kg lipopolysaccharide (LPS), and (iii) optimized rosiglitazone formulation. Twelve hours after the administration of the formulations, we sacrificed the animals and lavaged the lungs by instilling 5 mL of 0.9% saline into the trachea. After 30 s, we collected the BAL fluid and centrifuged at 500 ×g for 10 min, stored the supernatant at −20°C, later determined LDH and ALP levels using commercial assay-kits for LDH and ALP (Pointe Scientific, Canton, MI), and presented the enzyme levels in the BAL of LPS and formulation treated rats as fold increase against the enzyme levels in the BAL of the saline treated groups.
To assess whether the drug and PLGA particles of rosiglitazone produce any major toxicity after chronic administration, we treated healthy control rats with inratracheal (i) saline, (ii) 0.1 μg/kg lipopolysaccharide (LPS), (iii) plain rosiglitazone (15 mg/kg), and (iv) rosiglitazone particle (0.3 mg/kg rosiglitazone), once a day, for two weeks. After the treatment, we measured, in the BAL fluid, two inflammatory cytokines, IL-6 and TNF-α, using a commercial ELISA kits for rat IL-6 and TNF-α (Ray Biotech Inc., Norcross, GA). We also evaluated the extent of chronic inflammation by measuring CTRP1 (complement-C1q TNF-related protein 1) protein expression [22] . For this study, we treated the rats, once-a-day, with intratracheal (i) saline, (ii) plain rosiglitazone (15 mg/kg), and (iii) rosiglitazone particle (0.3 mg/ kg rosiglitazone) for three weeks and then collected the lung and visceral fat tissues. Using a CTRP1 antibody (Santa Cruz Biotechnology, Inc., Dallas, TX), we quantitated the expression of CTRP1 in the lungs and fat tissues by western blot analysis.
Absorption of rosiglitazone after oral, intravenous and intratracheal administration
For absorption studies, four groups (n = 3-4) of anesthetized male Sprague-Dawley rats with an average weight of 250 g, we gave 0.3 mg/ kg rosiglitazone in the following forms: (i) intravenous plain rosiglitazone, (ii) intratracheal plain rosiglitazone, (iii) oral plain rosiglitazone, (iv) oral rosiglitazone particles and (v) intratracheal rosiglitazone particles. For drug administration and blood sampling, we anesthetized the rats by an intramuscular injection of a cocktail of ketamine (90 mg/kg) and xylazine (10 mg/kg) and maintained the anesthesia with additional doses of the anesthetic cocktail, on an as-needed basis. Using an intratracheal aerosolizer for rats (Penn Century, Philadelphia, PA), we administered the formulations directly into the rat lungs and then collected the blood samples from the rat tail, centrifuged the samples at 17,000 ×g for 15 min to separate plasma, and finally stored the samples at −20°C for drug quantitation. For animal studies, we followed the NIH Guideline for the Care and Use of Laboratory Animals under an approved protocol (AM-10012).
We determined the concentration of rosiglitazone in rat plasma using an AB SCIEX QTRAP® 5500 tandem mass spectrometer (Framingham, MA), based on our previously established LC/MS/MS method [23] . After extracting the drug from the plasma by protein precipitation and using deuterated sildenafil as the internal standard, we followed the same chromatographic separation protocol as explained above in the studies for in vitro release profiles. We quantified the drug via multiple reaction monitoring (MRM) method, keeping the ESI source at a positive ionization mode, with the transitions of the parent ions to the product ions of m/z 358.2 → 135.2 for rosiglitazone and m/z 483.4 → 283.3 for deuterated sildenafil, respectively.
Hemodynamic efficacy in SUGEN-5416/hypoxia induced PAH rats
In a SUGEN-5416 plus hypoxia-induced PAH rats, we investigated the influence of optimized rosiglitazone particles on pulmonary hemodynamics [24, 25] . To induce PAH, we subcutaneously injected 20 mg/kg of SUGEN-5416 (Bio-Techne, Minneapolis, MO)−suspended in 0.5% carboxymethyl cellulose, 0.9% NaCl, 0.4% Tween 20 and 0.9% benzyl alcohol w/w in water−to male SD rats (n = 3-4) and then housed them in a hypoxia chamber (BioSpherix®, Lacona, NY) at 10% oxygen for 21 days with free access to food and water. On the 22nd day, we moved the rats to normoxia and divided them into five groups to receive (i) intratracheal saline (100 μL) as control, and 0.3 mg/kg rosiglitazone in the following forms: (ii) plain rosiglitazone oral, (iii) rosiglitazone particles oral (iv) intratracheal plain rosiglitazone, and (v) intratracheal rosiglitazone particles and measured the mean systemic arterial pressure (mSAP) and mean pulmonary arterial pressure (mPAP), as described below:
Before giving any treatments, we anesthetized the PAH rats by an intramuscular injection of ketamine and xylazine, shaved the ventral neck area and inserted a polyvinyl catheter (PV-1, Tygon®, Lima, OH), which we used to measure mPAP, into the right jugular vein and maneuvered the catheter through the right ventricle into the pulmonary artery. We then inserted a Millar® PV catheter (SPR-868, Millar, Inc., Houston, TX), to measure mSAP, into the left ventricle via the rightcarotid artery. We used a PowerLab™ 16/30 system−connected to a computer loaded with LabChart Pro™ 7.0 software (ADInstruments Inc., Colorado Springs, CO) and equipped with Millar® MPVS ultra system (Millar Inc., Houston, TX)−to record real-time mPAP and mSAP. MEMSCAP™ SP844 physiological pressure transducers (Memscap AS, Scoppum, Norway) attached to a bridge amplifier [26] recorded mPAP in a continuous fashion and the MPVS ultra system recorded mSAP. After recording the baseline pressure for 10 min, we treated the rats with one of the above formulations and monitored mPAP and mSAP for 3-6 h, and presented the data in initial percentage reduction of mPAP and mSAP, assuming the baseline pressure before the treatment was 100%.
The effects of rosiglitazone on human PAH-ECs and PAH-SMCs
We grew human pulmonary arterials ECs and SMCs (collected from PAH patients), upon receipt from the Pulmonary Hypertension Breakthrough Initiative (PHBI), in gelatin coated dishes using MV2 (PromoCell GmbH, Heidelberg, Germany) and SmGM (Lonza Inc., Williamsport, PA) media, respectively for 5-7 days until their confluency. For different experiments, we used PAH cells up to passage numbers P4 to P6 with population doublings up to 20. In 96-well plates, we seeded primary PAH-SMCs at a density of~10,000 cells per well in 200 μL of medium, treated with different concentration of rosiglitazone, and then incubated in a humidified incubator (37°C, 5% CO 2 ) for 24 or 48 h. We then incubated the rosiglitazone treated cells with 10 μL of Cell Counting Kit-8 (Sigma-Aldrich Inc., St. Louis, MO) for 2.5 h at 37°C, recorded the optical densities at 450 nm in a Synergy II microplate reader (BioTek Inc., Winooski, VT). We replicated each assay four times.
For western blot analysis, we treated PAH-ECs or PAH-SMCs with 10 μM and 100 μM rosiglitazone for 24 to 48 h depending on the protein to be assayed. After the treatment, we added cell lysis buffer (20 mM Tris HCl, pH 7.4; 15% Glycerol, 1% Triton X-100, 8 mM MgSO4, 150 mM NaCl, and 1 mM EDTA supplemented with β-glycerophosphate, 50 mM NaF, protease inhibitor, and phosphatase inhibitor), scrapped the cells off the flasks, vortexed and sonicated for 30 min, and centrifuged for 10 min at 10,000g at 4°C.
After resolving equal amounts of protein in SDS-PAGE, we blotted the samples onto polyvinylidene difluoride (PVDF) membranes (IPVH00010, Millipore, Burlington, MA), blocked with 5% BSA for 1 h, and then incubated the membranes overnight at 4°C with one of the four antibodies: anti-eNOS, anti-PPARγ anti-ET-1, anti-NOX4 and antiactin antibodies. Next day, after washing thrice with tris-buffered saline with Tween®-20, we incubated the membranes with HRPconjugated secondary antibody for an hour and again incubated with WesternSure® Enhanced Chemiluminescent substrate (LI-COR Biosciences, Lincoln, NE) for 1 min and finally visualized the membrane in a ChemDoc XRS System (Bio-Rad laboratories, Hercules, CA). Depending on protein's molecular weight, we used gel concentrations at 7.5-13.5% for immunoblotting.
Data analysis
We used repeated-measure ANOVA followed by a Fisher LSD posthoc analysis for statistical significance of the data presented in Fig. 4 . For other data, presented as mean ± SD, we used ANOVA with Tukey's multiple comparison analysis (OriginLab Corporation, Northampton, MA), considering p < 0.05 is statistically significant. Using Phoenix® WinNonlin (Certara USA, Inc., Princeton, NJ), we performed noncompartmental analysis and calculated the elimination half-life (t 1/2 ).
Results
Fabrication and physical characterization of PLGA particles of rosiglitazone
The process parameters that influence the major features of drugloaded PLGA particles−size, encapsulation efficiency, and the percentage drug loading−include PLGA concentration, homogenization rate, and concentration of surfactant, PVA, used as emulsifying agent. Polymer concentration, for example, influences the encapsulation efficiency and particle size [27] [28] [29] [30] ; homogenization speed and duration of homogenization affect the particle size of the final formulation [31] [32] [33] . Higher tangential stress, resulting from increased homogenization speed, reduces the droplet size of the double-emulsion and thus decreases the particle size. Because homogenization duration has no pronounced effect on the average particle diameter [33] , we selected the rate of homogenization as a critical process parameter. The concentration of PVA, a commonly used emulsifier that stabilizes the double-emulsion, in the external aqueous also influences the particle size distribution, drug entrapment, and the internal structure of the particles [34, 35] . To optimize the particles and identify the best process parameters for preparation of inhaled particles of rosiglitazone, we prepared 45 sets of formulations, using statistical design of experiment [19] (Minitab® 17; Minitab Inc., State College, PA) by varying the above three processes or input parameters: PLGA concentration, homogenization rate, and the concentration of PVA. The formulation optimization data presented in Fig. 1 suggest that PVA concentration, homogenization rate, the combined effects of PLGA concentration plus homogenization, and that of PLGA plus PVA concentration had major influence on rosiglitazone particle size (Fig. 1A) .
In general, increased surfactant concentration decreased particle size, although all process parameters showed some degree of effects on the size of the particles as is evident from the curvature of plots (Fig. 1A) . The changes in PLGA and PVA concentrations had an inverse Fig. 1 . Influence of PLGA concentration, homogenization rates and PVA concentration on particle size (A), entrapment efficiency (B), and drug loading percentage(C).
effect on encapsulation efficiency (Fig. 1B) . In case of percent drug loading, the most influential process parameters were PLGA concentration, homogenization rate, and the combined effect of PLGA concentration and homogenization rate. Increase in the PLGA concentration and homogenization rate decreased the percentage drug loading (Fig. 1C) . Based on the statistical response optimization (Supplementary Data, Fig. 1 ), we observed that the formulations prepared with 3% of PVA, 20% PLGA concentration and homogenized at 12,500 rpm yields reproducible and optimal particles for inhalational delivery. The volume based diameter of the optimized particles was 3.89 μm, which was close to expected particle size of 4 μm. The optimized particles were slightly porous and spherical in shape (Fig. 2A) ; the pores in the formulation may have resulted from the presence of PEI in the internal aqueous phase [18, 36, 37] . Deposition of inhaled particles over different regions of the lungs depends mostly on the aerodynamic behavior of the particles [38] . The MMAD, a parameter commonly used to assess the deposition patterns of inhaled drug products in the lung, of the optimized particle was 6.93 μm (Fig. 2B) . The average geometric diameter of the particles before and after the aerosolization were 6.6 ± 0.07 μm and 6.2 ± 0.02 μm, respectively, suggesting that the energy of aerosolization had no influence on particle size distribution.
Optimized particles showed prolong release properties in a simulated lung fluid
Based on previous studies, we assume that because of the hydrophobic nature of PLGA-based drug particles, rosiglitazone will liberate from the particles at a slower rate at physiological pH, as is observed 20% at 6 h [39] . Indeed, echoing the published report, the optimized particles released the drug in two separate phases: an initial surge (the burst phase) of the drug from the particles into the medium, followed by a stable and protracted release (Fig. 2C) . After the initial burst phase, the amount of drug released during the first 30 min, the drug continued to be released for 24 h. During the burst phase, 37.4 ± 2.2% drug gushed out of the particles in first 30 min and then over the next 24 h, 87.9 ± 6.7% drug came into the release medium.
PLGA particles of rosiglitazone produced protracted drug level in the blood without eliciting inflammatory reactions
Upon optimizing the PLGA particles of rosiglitazone, identifying the process parameters for fabrication of reproducible particles, and characterizing the formulations for physical properties and in vitro release profiles, we determined the absorption profile and acute safety of the formulations. In absorption studies, first we compared the absorption of plain drug after intravenous, oral, and intratracheal administration and then determined whether PLGA particles of rosiglitazone maintain the drug level in the blood for an extended time after intratracheal administration. We chose to use a dose of 0.3 mg/kg instead of 5-10 mg/ kg, based previously reported oral doses for rosiglitazone used in PAH rats [12, 40] , because we hypothesize that rosiglitazone, when given directly into the lungs, will produce pulmonary specific effect and thus can be used at a substantially reduced dose. We also assumed that reduced total dose will also minimize the side effect such as systemic hypotension.
Plain rosiglitazone, given intravenously, showed a rapid fall in blood levels with an elimination half-life (t 1/2 ) of 113.1 ± 20.5 min, but showed no absorption phase, as is expected for intravenously administered drugs (Fig. 3A) . The orally administered rosiglitazone, given either as the plain drug or PLGA particles of the drug, showed limited absorption with a drug concentration barely detectable in the blood (Fig. 3A) . Interestingly, the absorption curve for intratracheally administered rosiglitazone particles showed clear absorption and elimination phases with an elimination t 1/2 of 394 ± 109 min, which is about two-fold greater than that of plain intratracheal rosiglitazone. Later, we investigated the safety of the optimized formulations in vivo by measuring the levels of injury markers, LDH and ALP, in the BAL fluid after intratracheal administration of the optimized formulation. The levels of LDH and ALP in BALF, collected from the lungs treated with PLGA particles, were not significantly different from those observed in the BALF of lungs treated with saline (Fig. 3B) . Similarly, chronic administration of rosiglitazone particles for two weeks did not increase the levels of IL-6 and TNF-α while LPS, a known lung toxicant, and high dose rosiglitazone treatment caused substantial increase in these inflammatory markers (Fig. 3C ). Chronic treatment with the highdose rosiglitazone (15 mg/kg) was associated with elevated levels of IL-6 and TNF-α (Fig. 3C) . Lung tissues, which do not have basal CTRP1 expression (data not shown), did not show any expression of CTRP1, when the rats were treated with 0.3 mg/kg or 15 mg/kg rosiglitazone (Fig. 3D) . However, true to the published study, which suggest that the pro-inflammatory markers induces CTRP1 expression in adipose tissue [22] and in liver diseases [41] , we observed an increase in CTRP1 level in the adipose tissues of rats treated with 15 mg/kg rosiglitazone, but negligible expression of CTRP1 in rats treated with 0.3 mg/kg rosiglitazone, the dose used for inhalational delivery in the treatment of PAH (Fig. 3D) . Together, this data imply that optimized rosiglitazone particles do not elicit any reactivity to the particles upon acute and chronic exposure.
PLGA-based formulation and improve pulmonary hemodynamics in PAH rats
Previously, the efficacy of rosiglitazone in reducing mPAP has been studied in monocrotaline and hypoxia induced PAH animals [42] , but no studies compared the relative efficacy of the drug after oral versus intratracheal administration. We have also previously shown that anti-PAH drugs administered via the lungs produce more pulmonary specific vasodilation than those administered via the intravenous or oral routes [17] . In this study, we assessed the efficacy of both plain rosiglitazone and PLGA particles of rosiglitazone in reducing mPAP in SUGEN/hypoxia induced PAH rats, an animal model that closely resembles human PAH. PAH rats treated with saline or oral rosiglitazone evoked no changes in mPAP or mSAP (Fig. 4A-C) , reflecting the poor bioavailability of orally administered rosiglitazone or PLGA particles of rosiglitazine, given at a dose of 0.3 mg/kg (Fig. 3A) . In fact, the dose of rosiglitazone in our studies was~27-fold less than the dose used in previous studies [42] , whose goal was to demonstrate the anti-PAH effect of oral rosiglitazone [42] . Orally administered rosiglitazone did not give rise to enough drug levels in the lung vasculature to produce any therapeutic effect. However, the same dose of intratracheal plain rosiglitazone reduced the mPAP by~30% within 15 min (Fig. 4D ) and the differences between the magnitudes of mPAP and that of mSAP were statistically significant. On the other hand, pulmonary administration of optimized particles of rosiglitazone kept mPAP down for 6 h (Fig. 4E) . A point-by-point comparison of mPAP with mSAP between intratracheal plain vs PLGA particles of rosiglitazone shows that the differences between mPAP and mSAP were statistically significant for over~4.5 h.
Rosiglitazone balances the vasodilatory and vesoconstrictive mediators in human PAH-afflicted cells
Using PAH-afflicted human pulmonary arterial cells, PAH-ECs and PAH-SMCs, we investigated the efficacy of rosiglitazone in ameliorating Fig. 3. The drug absorption profiles (A) ; the levels of injury markers in the lungs after single formlation (B); the levels of inflammatory cytokiness in the lungs (C) and the expression of CTRP1 protein (D) after chronic intratracheal administration of the optimized rosiglitazone formulation. §p < 0.005, Ƶp < 0.001, ¥p < 0.0001. n = 3-4; Data represent mean ± SD. various cellular and molecular level changes that occurs in PAH patients. We studied the influence of rosiglitazone on the expression of eNOS in PAH-ECs both in hypoxic and normoxic conditions. Rosiglitazone, after 24 h of treatment, dose dependently increased the expression of eNOS in PAH-ECs, grown in both normoxia and hypoxia (Fig. 5A) . Rosiglitazone, when incubated with PAH-ECs for 48 h, also substantially increased eNOS expression in normoxic PAH-EC (Fig. 5A) . Our study also suggests that rosiglitazone increases PPAR-γ expression but decreases the expression of the vasoconstrictor, endothelin 1 (Fig. 5B) . Similarly, when we treated PAH-SMCs with rosiglitazone, the PPAR-γ expression levels rose (Fig. 5C ) but the levels of NOX-4 (Fig. 5C ), a cellular marker whose expression increases in PAH progression and thus assists in arterial remodeling [6, 43] , declined. All in all, similar to in vivo the efficacy study, the western blot analysis suggests that rosiglitazone, by balancing the expression of key molecular regulators in human PAH-ECs and SMCs, attenuates PAH progression.
Rosiglitazone prevents the proliferation of PAH-SMCs
In PAH, pulmonary arterial smooth muscle cells transition into an apoptosis-resistant hyper-proliferative phenotype and thus causes arterial muscularization and remodeling [44, 45] . True to the published data and mechanistic studies, presented above, rosiglitazone, with an IC50 of 57.19 μM, dose dependently inhibited the proliferation of PAHSMCs (Fig. 6 ).
Discussion
This study revolves around the development of a long-acting inhaled formulation of a commercially available drug with a goal to treat a rare disease, PAH. The major features or output parameters that we evaluated for the end products are the particles size, drug entrapment efficiency, and drug loading because these parameters are implicated in the respirability and dosing of drugs via the lungs. Particles with a geometric size range between 1 μm and 5 μm are known to be deposited the most in the alveolar regions, wherein drug absorption is maximum [46] [47] [48] . High drug encapsulation efficiency is eminently important for inhaled particulate delivery system because high drug content in particles means less total particulate matters in the lungs and thus reduced chances of particulate-matter-induced hazards. In addition to the drug entrapment, other factors such as particle geometric and aerodynamic diameters, a parameter that varies based on particle size and density, are optimized because these parameters dictate the deposition patterns or flight-path of airborne particles in the respiratory tract. We selected PLGA for this study because it is a US FDA and European Medicine Agency approved biocompatible and biodegradable carrier [49] . Moreover, PLGA eases surface modification, allows preparation of particles with surface pores, offers the flexibility of controlling release-rate by changing lactate-to-glycolate ratio and produces solid particles with improved stability.
Studies concerning particle optimization suggest that the encapsulation efficiency and percent drug loading depend on the polymer concentration, rate of homogenization during the secondary emulsion formation, and the concentration of emulsifying agent in the external aqueous phase. In terms of physicochemical properties and aerodynamic behavior, the optimized particles met the standard criteria of a respirable drug product. For encapsulation efficiency, PLGA and PVA concentrations, and the combined effect of PLGA concentration plus homogenization rate were the most significant factors. In the presence of PEI, a substance used to prepare porous particles, the hydrophobicity of PLGA decreases, and the osmotic gradient drives water out of external aqueous phase into the internal aqueous phase. Thus, PEI in the internal aqueous phase expands the volume of the double emulsion and subsequently yields larger and porous particles upon solvent evaporation [18, 37, 50] . Previous studies described the systematic optimization of nano-sized PLGA particles for intravenous for intravenous delivery [51, 52] . In contrast, this is the first study to report an approach of statistical design or Quality by Design (QbD) to prepare and optimize the impacts of input parameters on formulating respirable PLGA microparticles.
The initial spurt of release may have occurred from the dissolution of drug molecules adsorbed on the particle surface or diffusion of drugs from the particle core via the surface pore into the medium. The later slower release may have stemmed from self-erosion of porous particles upon interaction with the simulated lung fluid containing surfactants. The MMAD (6.92 μm) and microphotographs of the optimized formulation suggests that these particles were larger and porous enough to prolong the drug release from the particles due to the longer residence time in the lungs [37] . The process of aerosolization did not have any effect on particle size, as the volume-based diameters remained unchanged before and after aerosolization.
The absorption profile of plain drug and drug laden particles, presented in Fig. 3A , showed varying patterns depending on the route of administration and drug formulations: plain drug or drug-laden particles. The absorption pattern of intratracheally administered plain rosiglitazone was very similar to that of intravenous rosiglitazone with no apparent absorption phase and an elimination t 1/2 of 157.9 ± 20.3 min, a little longer than the t 1/2 for intravenous rosiglitazone, which may have resulted from slower absorption of the drug via the respiratory mucosa. Little or no drug levels were detected in the blood when plain rosiglitazone or PLGA particles of the drug were given orally, which may have stemmed from the degradation of the drug in the stomach or poor solubility of the drug in the intestinal fluid. Intratracheally administered PLGA particles of rosiglitazone showed a distinctly different shape of absorption curve although the dose of the drug was the same (0.3 mg/kg) as that used for the plain form of the drug given via three different routes. The prolongation in the elimination t 1/2 of intratracheal PLGA particles of rosiglitazone is the result of absorption controlled elimination, whereby the drug underwent elimination as the drug entered the blood from the respiratory mucosa. The drug absorption from the respiratory tract was possibly controlled by multiple factors including diffusion of surface-embedded drugs into respiratory fluid and erosion of particles submerged in the surfactant rich respiratory mucous, as is observed in vitro release studies. However, relative absorption after oral versus intravenous has not been assessed in this study because the intravenous route of administration is not amenable to injecting large porous particles that form a thick solution in contact with water and blood.
The in-vitro release profile of the optimized formulation in a simulated lung fluid echo the pharmacokinetic profiles in rats in prolonging the elimination half-life of the drug after pulmonary administration. However, given the inherent anatomic and metabolic differences between the respiratory tract of rodents and that of humans, translating these formulations from animals to humans may require a different release rate that can be achieved by using PLGA with a different lactate-to-glycolate ratio [53, 54] . Acute and chronic safety studies give information on the reactivity of the respiratory mucosa with PLGA particles. Although LPS treatment brought about~3-fold greater increase in ALP and LDH levels than the saline or particles treatment did, suggesting that LPS causes injury to the lungs but the formulation does not. Similarly, the chronic treatment with rosiglitazone particles, when administered at a dose of 0.3 mg/kg, was also safe to the animals as the levels of inflammatory cytokines (IL-6 and TNF-α) in particle treated rats were no different from that in vehicle treated rats. However, the drug induced injury markers in the lungs when the dose was increased to 15 mg/kg in the chronic treatment group. In adipose tissue, rosiglitazone improves insulin resistance by promoting the expression of CTRP1, an inducer of inflammatory condition [22, 55] . When the rats were treated with 0.3 mg/kg rosiglitazone for three weeks, CTRP1 expression increased neither in the lungs nor in the adipose. But there was an increase in CTRP1 protein levels in the adipose tissue of rats treated with 15 mg/kg rosiglitazone for three weeks. This result suggests that inhaled low-dose (0.3 mg/kg) rosiglitazone may not elicit any off-target effects such as hypotension or hypoglycemia while providing pulmonary specific anti-PAH effects.
The vasodilatory effect of intratracheal plain rosiglitazone was pulmonary selective. But the reduction in mPAP lasted only for 30 min and then it returned to the baseline value. Although intratracheal plain rosiglitazone initially reduced the mPAP in PAH rats, the plain form of the drug could not sustain the vasodilatory effects for long. Intratracheal administration of PLGA particles of rosiglitazone produced pulmonary selective vasodilation in PAH animals over an extended period with minimum effect on the systemic pressure; in this treatment group, mSAP was largely unaffected. This selective and prolonged reduction of mPAP by the rosiglitazone particles can be explained by the localized availability of rosiglitazone and slow release of the drug at the pulmonary vasculature. Importantly, the drug was effective in selectively lowering mPAP even when given at a dose 27-fold smaller than the oral dose, pointing to the superiority of the inhalational formulation over oral ones for the treatment of PAH. In fact, reduced dose perhaps was the reason for little or no effect of the drug in peripheral vasodilation.
The pulmonary vascular endothelium and smooth muscles are intimately implicated in the development of PAH [56, 57] . Many of the currently approved anti-PAH drugs work by increasing endothelial nitric oxide levels, an endothelium derived vasorelaxant produced by eNOS. But the levels of eNOS in PAH-ECs drop significantly compared with normal PAECs [15, 58] . Hypoxia, which contributes to the vascular remodeling in PAH via a different mechanism, also reduces the expression of eNOS by causing endothelial dysfunction [45, 59, 60] . Reduced PPAR-γ expression is associated with the development of PAH, but increased PPAR-γ expression lessens arterial remodeling in PAH [2, 11, 61] . The pathogenesis of PAH also entails an unusually greater level of endothelin-1, a powerful vasoconstrictor and proliferative cytokine of the pulmonary vasculature [16, 62] . Activation of PPAR-γ was previously reported to inhibit the proliferation of pulmonary arterial smooth muscle cells [44, 63] . In our study, rosiglitazone treatment, in both PAH-afflicted human ECs and SMCs, promotes vasodilation in the pulmonary arteries by readjusting the expression levels of both pro-and anti-vasodilatory protein markers, such as eNOS, PPAR-γ, and NOX-4 expression. Rosiglitazone also attenuated the proliferative changes in PAH-inflicted SMCs, pointing to rosiglitazone's potential in slowing the muscularization of pulmonary arteries. However, this study does not provide information concerning the role of rosiglitazone in the development of apoptosis resistant cells.
Conclusions
In this study, by modifying the PLGA concentration, homogenization rate and PVA concentration in a double-emulsion solvent-evaporation, we prepared inhalable sustained-release rosiglitazone particles with high drug entrapment and optimum physicochemical as well as aerodynamic properties. The in-vitro release profile of the optimized formulation in a simulated lung fluid echo the pharmacokinetic profiles in rats in prolonging the elimination half-life of the drug after pulmonary administration. Intratracheal administration of the optimized formulation of rosiglitazone produced pulmonary selective vasodilation in PAH animals over an extended period with minimum effect on the systemic pressure. Rosiglitazone not only inhibited the expression of key regulatory molecules responsible for PAH progression but also attenuated the proliferative changes in PAH-afflicted endothelial and smooth muscle cells. Overall, our study demonstrates that rosiglitazone can potentially be repurposed into an anti-PAH drug and inhaled PLGA particles of rosiglitazone would be more potent in selectively reducing mPAP than plain intratracheal or oral rosiglitazone, even when given at a much-reduced dose.
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